The federal appropriations bill under discussion in Congress includes a provision creating a streamlined pathway for Medicare coverage of FDA‑approved multi‑cancer early detection (MCED) tests. If enacted, the measure would let Medicare reimburse MCEDs at rates tied to existing multi‑target stool DNA screening payments and phase in age eligibility starting in 2029. The change addresses a major barrier for MCED firms: the current requirement for USPSTF endorsement before Medicare coverage. Analysts note the provision could materially affect MCED business models and reimbursement strategies, although coverage will hinge on final language and implementation timetables in the spending measure.